Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Adamas Finance Asia Subscribes For USD5 Million In PharmaJet Bonds (ALLISS)

LONDON (Alliance News) - Adamas Finance Asia Ltd on Monday proposed new investment in PharmaJet ...

Alliance News 14 January, 2019 | 11:39AM
Email Form

LONDON (Alliance News) - Adamas Finance Asia Ltd on Monday proposed new investment in PharmaJet Inc through convertible bonds.

PharmaJet has developed needle-free injectors to deliver medications and vaccines, which have received US Food & Drug Administration marketing clearance, CE Mark and World Health Organisation PQS certification.

PharmaJet's latest round of financing is targeting to raise between USD12 million and USD20 million for expansion of its business, particularly focused on Asia, and a potential initial public offering.

PharmaJet is contemplating an IPO in Singapore or New York in due course, and subject to market conditions.

Adamas said it intends to subscribe for up to USD5 million in the PharmaJet convertible bond offering.

"We are very excited with this proposed new investment in the medical devices sector which is experiencing rapid growth, particularly in Asia," said Adamas Chair John Croft.

"PharmaJet has developed and is marketing one of the leading needle-free injection solutions on the market which competes with traditional needle-syringe delivery devices," added Croft.

Adamas shares were untraded on Monday, last closing at USD0.60 each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Adamas Finance Asia Ord 24.00 GBX -12.73

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites